Tivantinib in hepatocellular carcinoma

Expert Opinion on Investigational Drugs

Volumn 22, Issue 1, 2013, Pages 141-147

  Trojan, Jörg ^a   Zeuzem, Stefan ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

Hepatocellular carcinoma; MET; Receptor tyrosine kinase inhibitor; Sorafenib; Tivantinib

Indexed keywords

BRIVANIB; PLACEBO; SCATTER FACTOR; SORAFENIB; TIVANTINIB;

ADVANCED CANCER; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; BLOOD TOXICITY; CANCER GROWTH; CANCER PROGNOSIS; DIARRHEA; DRUG BINDING; DRUG CONFORMATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG STRUCTURE; DRUG TREATMENT FAILURE; FATIGUE; GENE OVEREXPRESSION; HUMAN; IC 50; LEUKOPENIA; LIVER CELL CARCINOMA; MONOTHERAPY; NEUTROPENIA; NONHUMAN; OVERALL SURVIVAL; PHYSICIAN; PNEUMONIA; PRESCRIPTION; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; SEPTIC SHOCK; SIDE EFFECT; WEIGHT REDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; HUMANS; LIVER NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-MET; PYRROLIDINONES; QUINOLINES;

EID: 84871029860     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2013.741586     Document Type: Article

References (25)

1. Michalopoulos GK, De Frances MC. Liver regeneration. Science 1997;276:60-6
2. Huelsken J, Vogel R, Erdmann B, et al. β-Catenin controls hair follicle morphogenesis and stem cell differentiation in the skin. Cell 2001;105:533-45
3. Gherardi E, Birchmeier W, Birchmeier C, Vande Woude G. Targeting MET in cancer: rationale and progress. Nat Rev Cancer 2012;12:89-103
4. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
5. Erratum in: CA Cancer J Clin 2011;61:134
6. Ueki T, Fujimoto J, Suzuki T, et al. Expression of hepatocyte growth factor and its receptor, the c-met proto-oncogene, in hepatocellular carcinoma. Hepatology 1997;25:619-23
7. Kondo S, Ojima H, Tsuda H, et al. Clinical impact of c-Met expression and its gene amplification in hepatocellular carcinoma. Int J Clin Oncol 2012; Epub ahead of print
8. Kaposi-Novak P, Lee JS, Gòmez-Quiroz L, et al. Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype. J Clin Invest 2006;116:1582-95
9. Whittaker S, Marais R, Zhu AX. The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Oncogene 2010;29:4989-5005
10. Llovet JM, Ricci S, Mazzaferro V, et al. SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-90
11. European Association For The Study Of The Liver; European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012;56:908-43
12. Eathiraj S, Palma R, Volckova E, et al. Discovery of a novel mode of protein kinase inhibition characterized by the mechanism of inhibition of human mesenchymal-epithelial transition factor (c-Met) protein autophosphorylation by ARQ 197. J Biol Chem 2011;286:20666-76
13. Munshi N, Jeay S, Li Y, et al. ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity. Mol Cancer Ther 2010;9:1544-53
14. Mekhail T, Rich T, Rosen I, et al. Final results: a dose escalation phase 1 study of ARQ197, a selective c-MET inhibitor, in patients with metastatic solid tumors [abstract]. J Clin Oncol 2009;27:3548
15. Zucali P, Santoro A, Rodriguez-Lope C, et al. Final results from ARQ 197-114: A phase 1b safety trial evaluating the c-MET inhibitor ARQ197 in cirrhotic patients with hepatocellular carcinoma [abstract]. J Clin Oncol 2010;28:4137
16. Martell RE, Puzanov I, Ma WW, et al. Safety and efficacy of MET inhibitor tivantinib (ARQ 197) combined with sorafenib in patients with hepatocellular carcinoma (HCC) from a phase I study [abstract]. J Clin Oncol 2012;30:4117
17. Rimassa J, Porta C, Borbath I, et al. Tivantinib (ARQ 197) versus placebo in patients (pts) with hepatocellular carcinoma (HCC) who failed one systemic therapy: results of a randomized controlled phase II trial (RCT) [abstract]. J Clin Oncol 2012;30:4006
18. Llovet JM, Decaens T, Raoul JL, et al. Brivanib versus placebo in patients with advanced hepatocellular carcinoma (HCC) who failed or were intolerant to sorafenib: results from the phase 3 BRISK-PS study. EASL-The International Liver Congress; 2012.
19. Llovet JM, Pena CE, Lathia CD, et al. SHARP Investigators Study Group. Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma. Clin Cancer Res 2012;18:2290-300
20. Nishino T, Hisha H, Nishino N, et al. Hepatocyte growth factor as a hematopoietic regulator. Blood 1995;85:3093-100
21. Spigel DR, Ervin TJ, Ramlau R, et al. Final efficacy results from OAM4558g, a randomized phase II study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLC [abstract]. J Clin Oncol 2011;29:7505
22. Oliner KS, Tang R, Anderson A, et al. Evaluation of MET pathway biomarkers in a phase II study of rilotumumab (AMG 102) or placebo in combination with epirubicin, cisplatin, and capecitabine in patients with locally advanced or metastatic gastric or esophagogastric junction cancer [abstract]. J Clin Oncol 2012;30:4005
23. Kurzrock R, Sherman SI, Ball DW, et al. Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol 2011;29:2660-6
24. Verslype C, Cohn AL, Kelley RK, et al. Activityofcabozantinib (XL184) in hepatocellular carcinoma: results from a phase II randomized discontinuation trial (RDT) [abstract]. J Clin Oncol 2012;30:4007
25. Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012;366:883-92